查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
COVID-19 缓解产品全球市场2022-2029
市场调查报告书
商品编码
1140748

COVID-19 缓解产品全球市场2022-2029

Global COVID-19 Mitigation Products Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

FDA 举措的增加将推动市场增长。

随着 COVID-19 紧急情况的加剧，FDA 正在采取一些积极措施来接触供应链中的其他人，包括医疗设备製造商、医院和团购组织。 FDA 已与全球 1,000 多个设备製造基地建立联繫，重点关注虚拟设备和服务。外展活动将主要关注两种类型的虚拟设备：由于 COVID-19 大流行的爆发而需求量很大的设备，例如 PPE 和呼吸机，以及如果供应中断可能会出现短缺的设备。你给了它。 FDA 已授权一些没有 NIOSH（美国国家职业安全与健康研究所）许可的进口一次性呼吸器供医护人员使用，并已发布 EUA 以增加过滤式面罩呼吸器的供应。因此，由于加大了对医疗设备和服务普及的努力和战略，预计在预测期内市场将在全球范围内扩张。

地理渗透。

北美将是预测期内的主要地区。

据估计，在预测期内，北美地区将占据全球 COVID-19 缓解产品的最大市场份额。美国每10万人的冠状病毒死亡率低于一些欧洲国家。到2022年，美国医疗保健支出将达到3.3万亿美元，占全球医疗保健支出的42%以上。到 2020 年 3 月，国会批准了一项史无前例的 2.2 万亿美元 COVID-19 主要救助计划。这包括弗吉尼亚州、疾病预防控制中心、FDA、医疗保险、国家战略储备和 1610 亿美元的 COVID-19 疫苗。医院雇主协会报告的每月 500 亿美元的赤字不包括在内。 2020 年 8 月，CDC 开发了两项实验室测试来识别导致 COVID-19 的病毒 SARS-CoV-2。更新的这些测试也被用于测试甲型和乙型流感病毒。同时检测三种病毒将为公共卫生官员提供减少这些病毒在其社区中传播并保护稀缺资源所需的资讯。

拉丁美洲已成为全球 COVID-19 疫苗试验的主要地点，该病毒在社区中的广泛存在使开发人员能够测试疫苗功效。墨西哥还有来自法国赛诺菲、美国製药巨头强生和两家中国公司的后期临床试验。

竞争格局。

COVID-19 缓解产品具有很强的竞争力，包括多个主要和新兴市场参与者。全球 COVID-19 缓解产品市场包括3M Company、Abbott、Sanofi、Pfizer、Eli Lilly、Merck、3Scan、Advenio Technosys、Amara Health Analytics、Avalon等公司。主要参与者采用了多种增长战略，例如产品发布、临床试验、收购和合作伙伴关係，为 COVID-19 缓解产品的全球增长做出了贡献。例如，2020 年 1 月，Nihon Kohden 推出了 NKV-550 系列呼吸机系统，该系统提供了新生儿到成人重症监护环境所需的一整套应用。它是一款配备触摸面板并配备直观用户界面和屏幕帮助功能的呼吸机。 2020 年 4 月 2 日，生物技术领导者 Cresta International 推出了 Cresta Instant Hand Hygiene Solution，这是一种先进的手部消毒配方。这种革命性的产品提供即时 99.9% 的细菌保护，具有抗菌和防腐特性，使其成为全方位保护和清新的快速解决方案。 2020 年 3 月，再生元和赛诺菲还对多达 400 名患者的非处方关节炎药物 Kevzara（sarilumab）进行了评估，用于治疗严重的 COVID-19 冠状病毒感染，并在美国启动了 II/III 期临床项目。

全球 COVID-19 缓解产品市场报告将提供对大约 120 个市场数据表、131 个图表和 170 页的访问权限

内容

第 1 章调查方法及范围

  • 调查方法
  • 市场范围

第 2 章主要趋势和发展

第 3 章执行摘要

  • 按诊断产品和服务划分的市场细分
  • 按重症监护产品和服务划分的市场细分
  • 医疗 ICT 市场细分
  • 按製药行业产品划分的市场细分
  • 个人和防护装备市场细分
  • 与 COVID-19 相关的製造工厂的市场细分
  • 最终用户的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 促进因素
    • 抑制因素
    • 商机
  • 影响分析

第 5 章行业分析

  • 波特五力分析
  • 价值链分析
  • 专利分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措

第 7 章诊断设备和服务

  • 血清学检测试剂盒
  • 机器人 PCR 系统和软件
  • PCR 仪器和软件
  • 鼻腔和口腔拭子
  • PCR 试剂和耗材
  • 自采集PCR检测试剂盒
  • X射线检测设备
  • 其他

第 8 章重症监护产品和服务

  • 有创呼吸机
  • 无创呼吸机
  • 便携式呼吸机
  • 下一代呼吸机
  • 肾透析
  • 激增能力医院/ICU
  • 体外膜氧合器
  • 其他

第 9 章医疗 ICT 领域

  • E健康
  • 人工智能、大数据、深度学习
  • 区块链技术
  • 地理空间监测系统服务
  • 家庭医疗IT
  • 其他

第 10 章製药行业的副产品

  • 疫苗
  • 治疗药
  • 其他

第 11 章个人和防护装备

  • 医用手套
  • 医用口罩
  • 医用 PPE 长袍
  • 洗手液/表面消毒剂
  • 医用面罩
  • PPE 灭菌系统和耗材
  • 医疗眼保健
  • 其他

第 12 章 COVID-19 相关製造工厂

  • 呼吸机
  • 血清学检测试剂盒
  • 自取PCR检测试剂盒
  • PCR试剂
  • PCR系统
  • 手套
  • PPE 防护服
  • 其他

第 13 章最终用户

  • 医院
  • 紧急医疗服务 (EMS)
  • 实验室
  • 研究所
  • 家庭护理和疗养院
  • 诊所
  • 其他

第 14 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 15 章竞争格局

  • 竞争场景
  • 竞争对手战略分析
  • 市场情况/份额分析
  • 併购分析

第 16 章公司简介

  • 3M Company
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Abbott
  • Agilent Technologies
  • Medtronic
  • Pfizer
  • Qualaris Healthcare Solutions
  • Allscripts Healthcare Solutions
  • Agfa Healthcare
  • AbCellera
  • 3Scan
  • Sanofi
  • Advenio Technosys
  • Siemens
  • Amara Health Analytics
  • Regeneron Pharmaceuticals
  • Avalon
  • Eli Lilly
  • Merck
  • Koninklijke Philips NV

第17章 DataM

简介目录
Product Code: DMPH2606

Market Overview

COVID-19 Mitigation Products Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of YY% during the forecast period (2022-2029).

Mitigation products reduce the risk of contamination and slow the spread of COVID-19. The COVID-19 global pandemic has increased the demand for essential mitigation products and services. COVID-19 has put pressure on MedTech and the pharmaceutical industry, with high demand for diagnostic tests, vaccines, ventilators, personal protective equipment (PPE), and other essential medical supplies. The global COVID-19 mitigation market is growing due to several factors such as rising demand for COVID-19 vaccine, growing awareness towards protection from COVID-19 globally, and rising government and non-government organization's initiatives to meet the global demand for diagnostics, protection, and other products related to COVID-19.

Market Dynamics: Increase in FDA initiative drives market growth.

With high COVID-19 emergencies, the FDA has taken several proactive steps to contact medical device manufacturers and others in the supply chain, including hospitals and group purchasing organizations. The FDA has reached over 1,000 device manufacturing sites globally, focusing on virtual devices and services. The outreach has focused on two main types of virtual devices: those that are in high demand due to the COVID-19 pandemic outbreak, such as PPE and ventilators, and devices that may be prone to a potential shortage if there is a supply disruption. The FDA issued a EUA to increase the supply of filtering facepiece respirators by authorizing certain imported disposable respirators that are not the National Institute for Occupational Safety and Health (NIOSH)-approved for use by health care professionals. Hence, with increasing such efforts and strategies to increase the availability of devices and services, the market is expected to grow over the forecast period worldwide.

Market Segmentation: The ventilator segment is projected to be the dominant segment in the market during the forecast period.

The COVID-19 Related Manufacturing Plant segmented as Ventilators, Serologic Test Kits, Self-collection PCR Test Kits, PCR Reagents, PCR Systems, Gloves, PPE Gowns and others.

Advancements in mechanical ventilators aimed to provide improved services, settle on better choices, and improve patient comfort alongside the blending of pathophysiology, medicine, and engineering to enhance the quality of medical care in respiratory distresses. To meet rising demand worldwide, all ventilator manufacturers are ramping up their production, analyzing the criticality of the situation; even other companies, such as various leading US-based car manufacturing companies, are also considering manufacturing ventilators by teaming up with ventilator manufacturing companies to set up as many units as much as possible. It is estimated that in April 2020 that over 900,000 ventilators were in demand worldwide, with a shortage of 80,000 in the U.S. alone. Major companies that provide the U.S. with the devices include General Electric Co., Medtronic PLC, Hill-Rom Holdings Inc., ResMed Inc., and Sweden's Getinge AB are adopting various strategies to meet the rising demand. For instance, in the first three months of 2020, Dragerwerk AG & Co. KGaA saw a sharp rise, increasing by 116.7%. In the medical division, orders rose by 177.2%, driven primarily by demand for ventilators. On March 30th, 2020, Smiths Group contracted with the U.K. Government for a significant ramp-up in producing its life-saving Smiths Medical paraPAC plus™ ventilators. Production is expected to grow rapidly, increasing from hundreds a month to thousands a month to fulfill 10,000 units in response to the U.K. Government's challenge to U.K. technology and engineering businesses to help save lives in the coronavirus pandemic.

In pharma industry products segment, vaccine sub segment held significant share in the market.

The pharma industry is expected to grow significantly over the forecast period due to ongoing clinical trials for the COVID-19 vaccine. In August 2020, about 172 economies were engaged in discussions to participate in COVAX, a global initiative to work with vaccine manufacturers to provide countries with equal access to safe and effective vaccines when licensed and approved. COVAX has the largest and most diverse COVID-19 vaccine portfolio globally, including nine candidate vaccines, with a further nine under evaluation and conversations underway with other major producers. COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance, and the World Health Organization (WHO), in partnership with developed and developing country vaccine manufacturers. It is the only worldwide initiative working with governments and manufacturers to ensure that COVID-19 vaccines are available globally to higher- and lower-income countries.

Geographical Penetration: North America is the dominating region during the forecast period.

The North American region is estimated to dominate the global COVID-19 mitigation products accounting for the largest market share over the forecast period. The rate of coronavirus deaths per 100,000 people in the U.S. is lower than in several European countries. By 2022, U.S. healthcare spending stood at $3.3 trillion, more than 42% of global healthcare expenditures. By March 2020, Congress approved an unprecedented $2.2 trillion COVID-19 first relief package. It includes $161 Billion to the VA, CDC, FDA, Medicare, the Strategic National Stockpile, and COVID-19 Vaccines. It does not cover the $50 billion monthly deficit reported by the Hospitals Managers Association. In August 2020, CDC developed two laboratory tests identifying SARS-CoV-2, the virus that causes COVID-19. The newer of these tests are also used to test for influenza A and B viruses. Testing for all three viruses simultaneously will provide public health officials with the information they need to help reduce the spread of these viruses in the community while conserving resources in short supply.

Latin America has become a prime location for global COVID-19 vaccine trials, with widespread viruses in the community allowing developers to test their vaccines' efficiency. Mexico also carries out late-stage trials for France's Sanofi, U.S. pharmaceutical giant Johnson & Johnson, and two Chinese companies.

Competitive Landscape:

The COVID-19 mitigation products are highly competitive and consist of several major and new market players. Some of the global COVID-19 mitigation products markets are 3M Company, Abbott, Sanofi, Pfizer, Eli Lilly, Merck, 3Scan, Advenio Technosys, Amara Health Analytics, and Avalon, among others. The major players are adopting several growth strategies such as product launches, clinical trials, acquisitions, and collaborations, contributing to the growth of the COVID-19 Mitigation Products globally. For instance, On January 2020, Nihon Kohden debuted its NKV-550 Series Ventilator System, which offers a full suite of applications necessary in a critical care setting for neonates through adults. The ventilator features an integrated touchscreen, an intuitive user interface, and on-screen help functions. On April 2nd, 2020, Clensta International, a leading biotechnology company, launched the Clensta Instant Hand Hygiene Solution, advanced formula for hand sanitization. The novel product offers instant 99.9% germ protection with antimicrobial and antiseptic properties, establishing the new product as a quick solution for all-around protection and freshness. Also, In March 2020, Regeneron Pharmaceuticals and Sanofi launched a Phase II/III clinical program in the U.S. evaluating the marketed arthritis drug Kevzara (sarilumab) as a severe treatment for COVID-19 coronavirus infection in up to 400 patients.

The global COVID-19 mitigation products market report would provide an access to approximately 120 market data tables, 131 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Diagnostic Products and Services
  • 3.2. Market Snippet by Intensive Care Products & Services
  • 3.3. Market Snippet by Medical ICT
  • 3.4. Market Snippet by Pharma Industry Products
  • 3.5. Market Snippet by Personal & Protection Gear
  • 3.6. Market Snippet by COVID-19 Related Manufacturing Plant
  • 3.7. Market Snippet by End-User
  • 3.8. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Value chain analysis
  • 5.3. Patent Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Diagnostic Products and Services

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Diagnostic Products and Services Segment
    • 7.1.2. Market attractiveness index, By Diagnostic Products and Services Segment
  • 7.2. Serologic Test Kits*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Robotic PCR Systems & Software
  • 7.4. PCR Instrumentation & Software
  • 7.5. Nose & Mouth Swabs
  • 7.6. PCR Reagents & Consumables
  • 7.7. Self-collection PCR Test Kits
  • 7.8. X-Ray Procedures
  • 7.9. Others

8. By Intensive Care Products & Services

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Intensive Care Products & Services Segment
    • 8.1.2. Market attractiveness index, By Intensive Care Products & Services Segment
  • 8.2. Invasive Mechanical Ventilators *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Noninvasive Ventilators
  • 8.4. Portable Ventilators
  • 8.5. Next Generation Ventilators
  • 8.6. Kidney Dialysis
  • 8.7. Surge Capacity Hospitals & ICUs
  • 8.8. Extracorporeal Membrane Oxygenation Procedures
  • 8.9. Others

9. By Medical ICT

  • 9.1. Introduction
    • 9.1.1. Market size analysis, and y-o-y growth analysis (%), By Medical ICT Segment
    • 9.1.2. Market attractiveness index, By Medical ICT Segment
  • 9.2. E-Health *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 9.3. AI, Big Data & Deep Learning
  • 9.4. Blockchain Technologies
  • 9.5. Geo-Surveillance Systems & Services
  • 9.6. Homecare IT
  • 9.7. Others

10. By Pharma Industry Products

  • 10.1. Introduction
    • 10.1.1. Market size analysis, and y-o-y growth analysis (%), By Pharma Industry Products Segment
    • 10.1.2. Market attractiveness index, By Pharma Industry Products Segment
  • 10.2. Vaccines*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 10.3. Therapeutic Drugs
  • 10.4. Others

11. By Personal & Protection Gear

  • 11.1. Introduction
    • 11.1.1. Market size analysis, and y-o-y growth analysis (%), By Personal & Protection Gear Segment
    • 11.1.2. Market attractiveness index, By Personal & Protection Gear Segment
  • 11.2. Medical Gloves *
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 11.3. Medical Face Masks
  • 11.4. Medical PPE Gowns
  • 11.5. Hand & Surface Sanitizers
  • 11.6. Medical Face Shields
  • 11.7. PPE Sterilization: Systems & Consumables
  • 11.8. Medical Eye Protection
  • 11.9. Others

12. By COVID-19 Related Manufacturing Plant

  • 12.1. Introduction
    • 12.1.1. Market size analysis, and y-o-y growth analysis (%), By COVID-19 Related Manufacturing Plant Segment
    • 12.1.2. Market attractiveness index, By COVID-19 Related Manufacturing Plant Segment
  • 12.2. Ventilators*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 12.3. Serologic Test Kits
  • 12.4. Self-collection PCR Test Kits
  • 12.5. PCR Reagents
  • 12.6. PCR Systems
  • 12.7. Gloves
  • 12.8. PPE Gowns
  • 12.9. Others

13. By End-User

  • 13.1. Introduction
    • 13.1.1. Market size analysis, and y-o-y growth analysis (%), By End-User Segment
    • 13.1.2. Market attractiveness index, By End-User Segment
  • 13.2. Hospitals*
    • 13.2.1. Introduction
    • 13.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 13.3. Emergency Medical Services (EMS)
  • 13.4. Clinical Labs
  • 13.5. Research Bodies
  • 13.6. Homecare & Nursing Homes
  • 13.7. Clinics
  • 13.8. Others

14. By Region

  • 14.1. Introduction
    • 14.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 14.1.2. Market Attractiveness Index, By Region
  • 14.2. North America
    • 14.2.1. Introduction
    • 14.2.2. Key region-specific dynamics
    • 14.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 14.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 14.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 14.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 14.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 14.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 14.2.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 14.2.10. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 14.2.10.1. U.S.
      • 14.2.10.2. Canada
      • 14.2.10.3. Mexico
  • 14.3. South America
    • 14.3.1. Introduction
    • 14.3.2. Key Region-Specific Dynamics
    • 14.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 14.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 14.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 14.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 14.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 14.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 14.3.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 14.3.10. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 14.3.10.1. Brazil
      • 14.3.10.2. Argentina
      • 14.3.10.3. Rest of South America
  • 14.4. Europe
    • 14.4.1. Introduction
    • 14.4.2. Key Region-Specific Dynamics
    • 14.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 14.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 14.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 14.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 14.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 14.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 14.4.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 14.4.10. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 14.4.10.1. Germany
      • 14.4.10.2. U.K.
      • 14.4.10.3. France
      • 14.4.10.4. Spain
      • 14.4.10.5. Italy
      • 14.4.10.6. Rest of Europe
  • 14.5. Asia Pacific
    • 14.5.1. Introduction
    • 14.5.2. Key Region-Specific Dynamics
    • 14.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 14.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 14.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 14.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 14.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 14.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 14.5.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 14.5.10. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 14.5.10.1. China
      • 14.5.10.2. India
      • 14.5.10.3. Japan
      • 14.5.10.4. Australia
      • 14.5.10.5. Rest of Asia Pacific
  • 14.6. Middle East and Africa
    • 14.6.1. Introduction
    • 14.6.2. Key Region-Specific Dynamics
    • 14.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 14.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 14.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 14.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 14.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 14.6.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 14.6.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

15. Competitive Landscape

  • 15.1. Competitive scenario
  • 15.2. Competitor strategy analysis
  • 15.3. Market positioning/share analysis
  • 15.4. Mergers and acquisitions analysis

16. Company Profiles

  • 16.1. 3M Company*
    • 16.1.1. Company Overview
    • 16.1.2. Product Portfolio and Description
    • 16.1.3. Key Highlights
    • 16.1.4. Financial Overview
  • 16.2. Abbott
  • 16.3. Agilent Technologies
  • 16.4. Medtronic
  • 16.5. Pfizer
  • 16.6. Qualaris Healthcare Solutions
  • 16.7. Allscripts Healthcare Solutions
  • 16.8. Agfa Healthcare
  • 16.9. AbCellera
  • 16.10. 3Scan
  • 16.11. Sanofi
  • 16.12. Advenio Technosys
  • 16.13. Siemens
  • 16.14. Amara Health Analytics
  • 16.15. Regeneron Pharmaceuticals
  • 16.16. Avalon
  • 16.17. Eli Lilly
  • 16.18. Merck
  • 16.19. Koninklijke Philips NV
  • List not Exhaustive*

17. DataM

  • 17.1. Appendix
  • 17.2. About us and services
  • 17.3. Contact us